Of this, nearly 10% will be through an issue of fresh shares, with the proceeds to be utilised for bringing down the debt of the company, while the balance 90% will be an offer for sale by its promoter and private equity investor TPG Asia. The promoter holding will drop by 3.65 percentage points to 62.7% after the IPO.
Vijay Kedia buys 9 lakh shares of SME stock Mahamaya Lifesciences in Rs 12.5 crore block deal
Ace investor Vijay Kedia acquired a significant stake in Mahamaya Lifesciences through a block deal. He purchased nearly 9 lakh shares at Rs 140 each.